ELEVATE AS: ELEVATE Acceptability Study

Sponsor
University Ghent (Other)
Overall Status
Recruiting
CT.gov ID
NCT06136702
Collaborator
Horizon 2020 - European Commission (Other), Universidade Nova de Lisboa (Other), Universidad de Cuenca (Other), Hospital de Cancer de Barretos - Fundacao Pio XII (Other)
1,048
4
2
23.8
262
11

Study Details

Study Description

Brief Summary

This study includes a community-based, two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will be asked to take a self-sample on-site, followed by a follow-up assessment after 3 months. Attitudes, uptake and users' experiences related to the use of a HPV self-sampling test will be assessed, additionally, the impact on looking for follow up care of self-sampling with standard cervical screening strategies will be assessed and finally the feasibility of an HPV self-sampling in hard-to-reach groups versus educational sessions and standard care will be compared (arm 1 and 2).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Educational session
  • Behavioral: Self-sampling
  • Behavioral: Follow-up assessment
N/A

Detailed Description

ELEVATE, a five-year project conducted by an international research alliance led by Ghent University, aims to develop a new test and approach for cervical cancer screening in hard-to-reach populations. The test will combine self-sampling with a new low-cost, portable measurement device and will be validated in dedicated screening trials in Belgium, Brazil, Ecuador, and Portugal. The ELEVATE project targets women in Europe and Latin America who have never been screened or are not regularly screened. These women have a higher risk of developing cervical cancer. The project is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation Action, project number 825747.

To address the gaps in cervical cancer screening, the ELEVATE project is developing a screening strategy to make cervical screening more accessible to hard-to-reach women. This strategy will include the introduction of a new on-site HPV self-sampling screening tool and a portable testing device, able to detect the presence of HPV and cancer biomarker proteins. This portable, low-cost, on-site HPV testing tool will allow to streamline follow-up care for women at risk of developing cervical cancer.

This study is part of the ELEVATE project and takes place in hard-to-reach communities, focusing on socio-economically vulnerable women to assess the acceptability of educational sessions and self-sampling in these communities. This study includes a two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will be asked to take a self-sample on-site, followed by a follow-up assessment after 3 months. Attitudes, uptake and users' experiences related to the use of a HPV self-sampling test will be assessed, additionally, the impact on looking for follow up care of self-sampling with standard cervical screening strategies will be assessed and finally the feasibility of an HPV self-sampling in hard-to-reach groups versus educational sessions and standard care will be compared (arm 1 and 2).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1048 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
LongitudinalLongitudinal
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
EarLy dEtection of cerVical cAncer in Hard-to-reach Populations of Women Through Portable and Point-of-care HPV TEsting Acceptability Study
Actual Study Start Date :
Dec 7, 2022
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Educational session and follow-up assessment

A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake

Behavioral: Educational session
A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.

Behavioral: Follow-up assessment
To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.

Experimental: Educational session, self-sampling and follow-up assessment

A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. In addition, women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site. The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time.

Behavioral: Educational session
A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.

Behavioral: Self-sampling
Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.

Behavioral: Follow-up assessment
To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.

Outcome Measures

Primary Outcome Measures

  1. Uptake of cervical cancer screening [First encounter (day 0) and 3 months follow-up (day 90)]

    Compare the on-site uptake of self-sampling (arm2) with uptake of standard care (follow-up of arm1)

Secondary Outcome Measures

  1. Attitudes towards HPV self-sampling [First encounter (day 0)]

    Attitudes towards self-sampling: reasons to accept/decline the self-sample; advantages and disadvantages versus conventional screening.

  2. User's experiences of HPV self-sampling [First encounter (day 0)]

    User experiences among those who took a self-sample (easy/difficult; painless/painfull; trustworthy/untrusty; etc.)

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • are between the ages of 25 to 65 years of age, in line with the European Guidelines for initiating and stopping cervical cancer screening

  • (ever been) sexually active;

  • not diagnosed or in treatment for cervical cancer;

  • not having had a hysterectomy

  • not being pregnant

  • Speaking the local language

Exclusion Criteria:
  • younger than 25 years old or older than 65 years old

  • diagnosed or in treatment for cervical cancer

  • having had a hysterectomy

  • being pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 International centre for reproductive health Ghent East-Flanders Belgium 9000
2 Barretos Cancer Hospital - Fundação Pio XII Barretos Brazil
3 Universidad de Cuenca Cuenca Ecuador
4 Escola Nacional de Saúde Pública da Universidade NOVA de Lisboa Lisboa Portugal

Sponsors and Collaborators

  • University Ghent
  • Horizon 2020 - European Commission
  • Universidade Nova de Lisboa
  • Universidad de Cuenca
  • Hospital de Cancer de Barretos - Fundacao Pio XII

Investigators

  • Principal Investigator: Bernardo Vega Crespo, Universidad de Cuenca
  • Principal Investigator: Adhemar Longatto, Barretos Cancer Hospital
  • Principal Investigator: Sónia Dias, Universidade Nova de Lisboa
  • Principal Investigator: Olivier Degomme, University Ghent

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
University Ghent
ClinicalTrials.gov Identifier:
NCT06136702
Other Study ID Numbers:
  • ONZ-2022-0326
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023